Developing tools to eliminate river blindness in Africa
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10747884
This study is working to help get rid of river blindness in Africa by finding new ways to track how well treatments are working and to prevent the disease from coming back, using genetic tools to understand the parasites better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10747884 on ClinicalTrials.gov |
What this research studies
This research focuses on eliminating onchocerciasis, also known as river blindness, caused by the Onchocerca volvulus parasite in Africa. It aims to sustain drug effectiveness and prevent the return of the disease by creating new genetic tools to monitor how well the treatment works over time. The researchers will analyze genetic data from adult female worms to identify markers that predict treatment response and develop a mathematical model to assess the risk of disease resurgence. This approach combines genetic analysis with advanced modeling techniques to ensure long-term success in controlling the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in endemic areas of Africa who are at risk of onchocerciasis or have been treated for the disease.
Not a fit: Patients who do not reside in endemic regions or those who have not been treated for onchocerciasis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the effective elimination of river blindness, improving the quality of life for millions of people in affected regions.
How similar studies have performed: Previous research has shown success in using genetic tools and community-directed treatment strategies to combat similar infectious diseases, indicating a promising approach for this project.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MITREVA, MAKEDONKA — WASHINGTON UNIVERSITY
- Study coordinator: MITREVA, MAKEDONKA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.